OpenAI released a model built for drug discovery
GPT-Rosalind, previewed in April 2026 with Amgen and Moderna, was the company's first reasoning model for one field.
Kivorent News desk, published , 1 min read
6 of 11lab benchmark tasks where it beat GPT-5.4
This is a look back at an event from . We wrote it on November 11, 2026, from the sources listed at the end.
OpenAI launched GPT-Rosalind on April 16, 2026, as a research preview. It is the company's first reasoning model built for a single field: drug discovery and genomics. Early access went to Amgen, Moderna, the Allen Institute and Thermo Fisher, according to AI Weekly.
On LABBench2, a set of 11 laboratory research tasks, it beat the general-purpose GPT-5.4 on six.
Why it mattered
AI companies had mostly built one model for everything. A model trained for biology is a bet that specialist versions will do better where the work is technical and the data is unusual.
Six of 11 is a modest margin, and a benchmark is not a new medicine. Drug discovery takes years, and the test of a tool like this is whether candidates it helps find survive clinical trials.
This article is general information about how technology works. It is not medical advice. Talk to a clinician about your own health.
Sources
- Generative AI: Anthropic just retook the frontier, quietly, AI Weekly, week of April 11 to 18, 2026
OpenAIDigital health and AI in careAI models
Spotted an error? Tell us and we will fix it.